ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1539

Microscopic Polyangiitis: A Large Single Center Series

Leslie D. Wilke1, Guy P. Fiocco2 and Marilyn Prince-Fiocco3, 1Division of Pulmonary, Critical Care and Sleep Medicine, Scott & White Memorial Center, Temple, TX, 2Division of Rheumatology, Scott & White Clinic, Temple, TX, 3Temple, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Polyangiitis and pulmonary complications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Microscopic polyangiitis (MPA) is a rare systemic, ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis of unclear etiology, characterized by necrotizing small vessel involvement with few or no immune complex deposits.  Necrotizing glomerulonephritis is common. Pulmonary capillaritis causing alveolar hemorrhage and hemoptysis is well-recognized, but most case series are reported in the nephrology literature and emphasize renal considerations (1). We present a single center 10-year retrospective review of 40 patients meeting the Chapel Hill Consensus Conference case definition of MPA, with specific p-ANCA and MPO (myeloperoxidase) positivity, with emphasis on initial and subsequent pulmonary manifestations.

Methods:

We searched the electronic data base as well as separate databases in our laboratory within our large integrated clinic-hospital system and reviewed charts of all patients with related ICD-9 codes for “vasculitis” in the last 10 years.  Patients included in the study were both p-ANCA and MPO positive and met clinical and pathologic criteria for MPA. Patients with only c-ANCA disease or significant granulomata on pathologic evaluation were excluded. Several variables were reviewed (Table 1).

Results:

Onset of illness was usually abrupt and included respiratory symptoms. Most common presenting complaint was cough.  Hemoptysis occurred during the course of illness in 40%.

Pulmonary evaluation included bronchoscopy in 60% and surgical lung biopsy in 12%, usually related to pulmonary hemorrhage.

Treatment doses and duration were quite variable but included combination corticosteroids and cytotoxic therapy in 60%.  Therapy was directed by nephrology in 52.5%.  Rheumatology and Pulmonary directed therapy in 22.5% patients each.  One patient did not undergo therapy.  

The course of illness was variable, with few significant pulmonary relapses.  Hemodialysis occurred in 28%.  Known deaths occurred in twelve, with none directly attributable to the disease process.

Conclusion:

1) Pulmonary involvement is much more frequent than the current literature report of 25-50% when features in addition to hemorrhage are recorded. (1,2)

2) MPA at onset usually includes respiratory symptoms.  Demographic and medical variables failed to identify predisposing factors.

3) No clear guidelines direct the evaluation and management of MPA patients. Consistent communication between pulmonary, nephrology, and rheumatology services could improve our understanding of the disease process.

 

Characteristic

N = 40

Mean Age at Diagnosis

58.9 years  (range:14-83 years)

Gender

 

    Male

37.5%(15)

    Female

62.5%(25)

    Male:Female ratio

1:1.6

Race

 

    White

73%(29)

    Black

5%(2)

    Hispanic

20%(8)

    Other

2.5%(1)

Vital status as of 2011

 

    Alive

60%(24)

    Deceased

30%(12)

    Unknown

10%(4)

Smoking history prior to diagnosis

50%(20)

Patients who underwent pulmonary function testing

42.5%(17)

    FEV1/FVC >70

70.5%(12 of 17)

Pulmonary involvement only

5%(2)

Renal involvement only

12.5%(5)

Pulmonary and renal involvement

75%(30)

Hemoptysis

40%(16)

Concomitant Medical History

 

    Positive ANA

18(45%)

    Hypertension

57.5%(23)

    Diabetes mellitus

20%(8)

Cr >1.5 at time of diagnosis

62.5%(25)

Progression to hemodialysis

27.5%(11)

Diagnostic modalities

 

     Bronchoscopy

60%(24)

     Renal Biopsy

60%(24)

     Lung Biopsy

12.5%(5)

      Other Biopsy

10%(4)

      Clinical Diagnosis

15%(6)

Treatment

 

     Cyclophosphamide + Corticosteroids

60%(24)

     Corticosteroids Alone

10%(4)

     Azathioprine Alone

5%(2)

     Azathioprine + Corticosteroids

10(4)

     Rituximab

5%(2)

     Mycophenolate mofetil

12.5%(5)

     Cyclophosphamide + Corticosteroids  + Plasmapheresis

5%(2)

     Corticosteroids + Rituximab + Mycophenolate +

         Plasmapheresis

2.5%(1)

     No Treatment

2.5%(1)

REFERENCES:

  1. Frankel SK, Cosgrove GP, Fischer A, Meehan RT, Brown KK.  Update in the diagnosis and management of pulmonary vasculitis.  Chest.  2006; 129:452-465.
  2. Chung SA, Seo P.  Microscopic Polyangiitis.  Rheumatology Disease Clinic of North America.  2010; 36:545-558.

Disclosure:

L. D. Wilke,
None;

G. P. Fiocco,
None;

M. Prince-Fiocco,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microscopic-polyangiitis-a-large-single-center-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology